# Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

> **NCT03685890** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 74 (estimated)

## Conditions studied

- Melanoma
- In-Transit Metastasis

## Interventions

- **DRUG:** Nivolumab
- **PROCEDURE:** Isolated limb perfusion (ILP)

## Key facts

- **NCT ID:** NCT03685890
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685890, "Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03685890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*